+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bronchiectasis - Pipeline Review, H1 2020

  • ID: 5024758
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 90 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Insmed Inc
  • Kamada Ltd
  • Novabiotics Ltd
  • OrPro Therapeutics Inc
  • Parion Sciences Inc
  • MORE
Bronchiectasis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Insmed Inc
  • Kamada Ltd
  • Novabiotics Ltd
  • OrPro Therapeutics Inc
  • Parion Sciences Inc
  • MORE
  • Introduction
  • Report Coverage
  • Bronchiectasis - Overview
  • Bronchiectasis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Bronchiectasis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bronchiectasis - Companies Involved in Therapeutics Development
  • Alitair Pharmaceuticals Inc
  • Chiesi Farmaceutici SpA
  • Helperby Therapeutics Group Ltd
  • Insmed Inc
  • Kamada Ltd
  • Novabiotics Ltd
  • OrPro Therapeutics Inc
  • Parion Sciences Inc
  • Polyphor AG
  • Recipharm AB
  • Santhera Pharmaceuticals Holding AG
  • Savara Inc
  • Therapeutic Systems Research Laboratories Inc
  • Zambon Co SpA
  • Bronchiectasis - Drug Profiles
  • alpha-1 proteinase inhibitor (human) second generation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • amikacin sulfate PR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARD-3150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brensocatib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CHF-6333 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • doxofylline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • erdosteine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HY-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • murepavadin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCFBE-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NM-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORP-100S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • POL-6014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Bronchiectasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tobramycin + triclosan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bronchiectasis - Dormant Projects
  • Bronchiectasis - Discontinued Products
  • Bronchiectasis - Product Development Milestones
  • Featured News & Press Releases
  • Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
  • Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
  • Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
  • May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007
  • Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
  • Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis
  • Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product
  • Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
  • Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Bronchiectasis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, H1 2020
  • Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H1 2020
  • Bronchiectasis - Pipeline by Helperby Therapeutics Group Ltd, H1 2020
  • Bronchiectasis - Pipeline by Insmed Inc, H1 2020
  • Bronchiectasis - Pipeline by Kamada Ltd, H1 2020
  • Bronchiectasis - Pipeline by Novabiotics Ltd, H1 2020
  • Bronchiectasis - Pipeline by OrPro Therapeutics Inc, H1 2020
  • Bronchiectasis - Pipeline by Parion Sciences Inc, H1 2020
  • Bronchiectasis - Pipeline by Polyphor AG, H1 2020
  • Bronchiectasis - Pipeline by Recipharm AB, H1 2020
  • Bronchiectasis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
  • Bronchiectasis - Pipeline by Savara Inc, H1 2020
  • Bronchiectasis - Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020
  • Bronchiectasis - Pipeline by Zambon Co SpA, H1 2020
  • Bronchiectasis - Dormant Projects, H1 2020
  • Bronchiectasis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Bronchiectasis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Bronchiectasis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • Alitair Pharmaceuticals Inc
  • Chiesi Farmaceutici SpA
  • Helperby Therapeutics Group Ltd
  • Insmed Inc
  • Kamada Ltd
  • Novabiotics Ltd
  • OrPro Therapeutics Inc
  • Parion Sciences Inc
  • Polyphor AG
  • Recipharm AB
  • Santhera Pharmaceuticals Holding AG
  • Savara Inc
  • Therapeutic Systems Research Laboratories Inc
  • Zambon Co SpA
Note: Product cover images may vary from those shown
Adroll
adroll